Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 1 SPEC. ISS., 2005, Pages 129-142

  Morris, Emma C ^a,b   Mackinnon, Stephen ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Low grade non Hodgkin's lymphoma; Reduced intensity allogeneic stem cell transplantation

Indexed keywords

ALEMTUZUMAB; BCR ABL PROTEIN; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; METHOTREXATE; PROTEIN BCL 2; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG MEGADOSE; FEASIBILITY STUDY; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LYMPHOCYTE TRANSFUSION; MEDICAL DECISION MAKING; MEDICAL LITERATURE; NONHODGKIN LYMPHOMA; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 13344280999     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.08.015     Document Type: Review

References (38)

1. S.J. Horning Natural history of and therapy for the indolent non-Hodgkin's lymphomas Seminars in Oncology 20 1993 75-88
2. J.O. Armitage & D.D. Weisenburger New directions for child and adolescent development. Non-Hodgkin's Lymphoma Classification Project Journal of Clinical Oncology 16 1998 2780-2795
3. T. Philip C. Guglielmi A. Hagenbeek et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma The New England Journal Of Medicine 316 1987 1493-1498
4. J.G. Gribben A.H. Goldstone D.C. Linch et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy Journal of Clinical Oncology 7 1989 1621-1629
5. C.J. Gallagher W.M. Gregory A.E. Jones et al. Follicular lymphoma: prognostic factors for response and survival Journal of Clinical Oncology 4 1986 1470-1480
6. R. Chopra A.H. Goldstone R. Pearce et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case controlled analysis of European Bone Marrow Transplant Group registry data Journal of Clinical Oncology 10 1992 1690-1695
7. L.F. Verdonck A. Dekker H.M. Lokhorst et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma Blood 90 1997 4201-4205
8. K.W. van Besien I.F. Khouri S.A. Giralt et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management Journal of Clinical Oncology 13 1995 1096-1102
9. M.M. Horowitz R.P. Gale P.M. Sondel et al. Graft-versus-leukemia reactions after bone marrow transplantation Blood 75 1990 555-562
10. M. Sykes G.L. Szot K.A. Swenson et al. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning Nature Medicine 3 1997 783-787
11. M.Y. Mapara M. Pelot G. Zhao et al. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance Biology of Blood and Marrow Transplantation 7 2001 646-655
12. M. Sykes M.A. Sheard & D.H. Sachs Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells The Journal of Experimental Medicine 168 1988 2391-2396
13. M.R. Pelot D.A. Pearson K. Swenson et al. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen Biology of Blood and Marrow Transplantation 5 1999 133-143
14. S. Mackinnon L. Barnett G. Heller et al. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia Blood 83 1994 3409-3416
15. M.Y. Mapara Y.M. Kim S.P. Wang et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells Blood 100 2002 1903-1909
16. W.D. Shlomchik M.S. Couzens C.B. Tang et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells Science 285 1999 412-415
17. I.F. Khouri M. Keating M. Korbling et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplant Journal of Clinical Oncology 16 1998 2817-2824
18. A. Nagler S. Slavin G. Varadi et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma Bone marrow transplantation 25 2000 1021-1028
19. I.F. Khouri R.M. Saliba S.A. Giralt et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality Blood 98 2001 3595-3599
20. P.A. McSweeney D. Niederwieser J.A. Shizuru et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390-3400
21. P.D. Kottaridis D. Milligan R. Chopra et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2000 2419-2425
22. E.C. Morris K. Thomson C. Craddock et al. Outcome following Alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL) Blood 2004 in press
23. R.D. Faulkner C. Craddock J.L. Byrne et al. Campath reduced intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity and survival in 65 patients Blood 103 2004 428-434
24. A.Y.L. Ho S. Devereux G.J. Mufti & A. Pagliuca Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions Bone marrow transplantation 31 2003 551-557
25. I.F. Khouri M.S. Lee R.M. Saliba et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: Impact of rituximab on immunomodulation and survival Experimental Hematology 32 2004 28-35
26. P. Dreger R. Brand J. Hansz Chronic Leukemia Working Party of the EBMT et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning Leukemia 17 2003 841-848
27. K.S. Peggs K. Thomson D.P. Hart et al. Dose escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism, and disease responses Blood 103 2004 1548-1556
28. A. Lopez-Guillermo F. Cabanillas T.I. McDonnell et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma Blood 93 1999 3081-3087
29. A. Lopez-Guillermo F. Cabanillas P. McLaughlin et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series Annals of Oncology 11 supplement 1 2000 137-140
30. F. Lin M.A. Kirkland F.V. Van Rhee et al. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia Bone Marrow Transplantation 18 1996 1147-1152
31. E. Olavarria E. Kanfer R. Szydlo et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia Blood 97 2001 1560-1565
32. T. Philip C. Gugliemi A. Hagenbeek et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma The New England Journal of Medicine 333 1995 1540-1545
33. A.S. Freedman D. Neuberg P. Mauch et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood 94 1999 3325-3333
34. J.G. Gribben D. Neuberg A.S. Freedman et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma Blood 81 1993 3449-3457
35. S.J. Horning R.S. Negrin R.T. Hoppe et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial Blood 97 2001 404-409
36. A.M. Carella M. Cavaliere E. Lerma et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and peripheral blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma Journal of Clinical Oncology 18 2000 3918-3924
37. R. Chakraverty K. Peggs R. Chopra et al. Limiting transplantation-related mortality folowwing unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood 99 2002 1071-1078
38. S.P. Robinson A.H. Goldstone S. Mackinnon et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Blood 99 2002 2670-2676